PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

PHASE1RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Alzheimer Disease, Early Onset
Interventions
DRUG

PMN310

A humanized immunoglobulin G1 (IgG1) monoclonal antibody

DRUG

Placebo

0.9% NaCl 100 mL

Trial Locations (22)

12208

RECRUITING

Alzheimer's Disease Research Center, Albany

19462

RECRUITING

Keystone Clinical Studies, LLC, Plymouth Meeting

28105

RECRUITING

Flourish Research, Matthews

30030

RECRUITING

CenExel iResearch, LLC, Decatur

31909

RECRUITING

Columbus Memory Center, LLC, Columbus

32162

RECRUITING

Charter Research, The Villages

32789

RECRUITING

Conquest Research, LLC, Winter Park

32803

RECRUITING

Charter Research, Orlando

33126

RECRUITING

Finlay Medical Research, Miami

33135

RECRUITING

Gonzalez MD and Aswad MD Health Services, Optimus U Corp, Miami

33414

RECRUITING

Alzheimer's Research and Treatment Center, Wellington

33442

RECRUITING

Quantum Laboratories, Deerfield Beach

33445

RECRUITING

Brain Matters Research, Delray Beach

33462

RECRUITING

JEM Research Institute, Atlantis

34470

RECRUITING

Renstar Medical Research, Ocala

34997

RECRUITING

Alzheimer's Research and Treatment Center, Stuart

44720

RECRUITING

Neuro Behavioral Clinical Research, Inc., North Canton

75231

RECRUITING

Kerwin Medical Center, Dallas

90804

RECRUITING

Healthy Brain Research, Long Beach

92614

RECRUITING

Irvine Center for Clinical Research, Irvine

02360

RECRUITING

Headlands Eastern MA LLC, Plymouth

08755

RECRUITING

Advanced Memory Research Institute of NJ, Toms River

Sponsors
All Listed Sponsors
lead

ProMis Neurosciences, Inc

INDUSTRY

NCT06750432 - PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) | Biotech Hunter | Biotech Hunter